Ad is loading...
CELC
Price
$12.66
Change
-$1.45 (-10.28%)
Updated
Nov 15 closing price
123 days until earnings call
ENTA
Price
$9.53
Change
-$0.60 (-5.92%)
Updated
Nov 15 closing price
8 days until earnings call
Ad is loading...

CELC vs ENTA

Header iconCELC vs ENTA Comparison
Open Charts CELC vs ENTABanner chart's image
Celcuity
Price$12.66
Change-$1.45 (-10.28%)
Volume$954.23K
CapitalizationN/A
Enanta Pharmaceuticals
Price$9.53
Change-$0.60 (-5.92%)
Volume$157.7K
CapitalizationN/A
CELC vs ENTA Comparison Chart
Loading...
CELC
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ENTA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
CELC vs. ENTA commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELC is a Sell and ENTA is a Sell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (CELC: $12.66 vs. ENTA: $9.53)
Brand notoriety: CELC and ENTA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELC: 347% vs. ENTA: 102%
Market capitalization -- CELC: $468.8M vs. ENTA: $201.93M
CELC [@Biotechnology] is valued at $468.8M. ENTA’s [@Biotechnology] market capitalization is $201.93M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELC’s FA Score shows that 0 FA rating(s) are green whileENTA’s FA Score has 1 green FA rating(s).

  • CELC’s FA Score: 0 green, 5 red.
  • ENTA’s FA Score: 1 green, 4 red.
According to our system of comparison, both CELC and ENTA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELC’s TA Score shows that 5 TA indicator(s) are bullish while ENTA’s TA Score has 5 bullish TA indicator(s).

  • CELC’s TA Score: 5 bullish, 5 bearish.
  • ENTA’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both CELC and ENTA are a good buy in the short-term.

Price Growth

CELC (@Biotechnology) experienced а -20.13% price change this week, while ENTA (@Biotechnology) price change was -13.91% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

CELC is expected to report earnings on Mar 20, 2025.

ENTA is expected to report earnings on Feb 05, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CELC($469M) has a higher market cap than ENTA($202M). ENTA YTD gains are higher at: 1.275 vs. CELC (-13.109). CELC has higher annual earnings (EBITDA): -76.03M vs. ENTA (-104.08M). CELC has more cash in the bank: 283M vs. ENTA (230M). ENTA has less debt than CELC: ENTA (50.6M) vs CELC (96.5M). ENTA has higher revenues than CELC: ENTA (72M) vs CELC (0).
CELCENTACELC / ENTA
Capitalization469M202M232%
EBITDA-76.03M-104.08M73%
Gain YTD-13.1091.275-1,028%
P/E RatioN/AN/A-
Revenue072M-
Total Cash283M230M123%
Total Debt96.5M50.6M191%
FUNDAMENTALS RATINGS
CELC vs ENTA: Fundamental Ratings
CELC
ENTA
OUTLOOK RATING
1..100
7255
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
95
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9596
PRICE GROWTH RATING
1..100
6564
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CELC's Valuation (36) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for ENTA (95) in the Biotechnology industry. This means that CELC’s stock grew somewhat faster than ENTA’s over the last 12 months.

CELC's Profit vs Risk Rating (100) in the Miscellaneous Commercial Services industry is in the same range as ENTA (100) in the Biotechnology industry. This means that CELC’s stock grew similarly to ENTA’s over the last 12 months.

CELC's SMR Rating (95) in the Miscellaneous Commercial Services industry is in the same range as ENTA (96) in the Biotechnology industry. This means that CELC’s stock grew similarly to ENTA’s over the last 12 months.

ENTA's Price Growth Rating (64) in the Biotechnology industry is in the same range as CELC (65) in the Miscellaneous Commercial Services industry. This means that ENTA’s stock grew similarly to CELC’s over the last 12 months.

ENTA's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for CELC (100) in the Miscellaneous Commercial Services industry. This means that ENTA’s stock grew significantly faster than CELC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CELCENTA
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
68%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
65%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
84%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 20 days ago
83%
Bullish Trend 12 days ago
70%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
62%
Aroon
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
72%
View a ticker or compare two or three
Ad is loading...
CELC
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ENTA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NQCAX5.30N/A
N/A
Nuveen Large Cap Value Opportunities A
AUICX35.03-0.27
-0.76%
AB Equity Income C
CZMSX17.38-0.21
-1.19%
Multi-Manager Small Cap Eq Strat Inst
MITGX36.84-0.45
-1.21%
MFS Massachusetts Investors Tr R1
VYSYX12.67-0.18
-1.40%
Voya Small Company A

CELC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CELC has been loosely correlated with PLRX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CELC jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELC
1D Price
Change %
CELC100%
-10.28%
PLRX - CELC
42%
Loosely correlated
-3.27%
INZY - CELC
41%
Loosely correlated
-8.89%
SNDX - CELC
41%
Loosely correlated
-5.72%
QSI - CELC
39%
Loosely correlated
-5.77%
ENTA - CELC
39%
Loosely correlated
-5.92%
More

ENTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with ARWR. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then ARWR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
-5.92%
ARWR - ENTA
43%
Loosely correlated
-13.26%
INZY - ENTA
42%
Loosely correlated
-8.89%
ETNB - ENTA
41%
Loosely correlated
-9.37%
GBIO - ENTA
40%
Loosely correlated
-8.33%
KROS - ENTA
39%
Loosely correlated
-6.18%
More